ENTA
Enanta
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 4
Sell signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Keeps Dropping
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ENTA
Enanta Pharmaceuticals, Inc.
A company that developing small molecule drugs for viral infections and liver diseases
Biological Technology
Invalid Date
03/21/2013
NASDAQ Stock Exchange
131
09-30
Common stock
4 Kingsbury Avenue , Watertown, Massachusetts 02472
--
Enanta Pharmaceuticals, Inc., was incorporated in 1995 under the laws of the State of Delaware. The company is a biotechnology company that is a leader in small molecule drug discovery and development, using robustness, chemically driven methods and drug discovery capabilities, with a focus on the treatment of viral infections. The company discovered gleCAPrevir, the second of two protease inhibitors discovered and developed in collaboration with Abbvie for the treatment of chronic infection with hepatitis C virus (HCV).
Company Financials
EPS
ENTA has released its 2025 Q2 earnings. EPS was reported at -1.06, versus the expected -1.14, beating expectations. The chart below visualizes how ENTA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ENTA has released its 2025 Q2 earnings report, with revenue of 14.93M, reflecting a YoY change of -12.48%, and net profit of -22.64M, showing a YoY change of 27.32%. The Sankey diagram below clearly presents ENTA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
